First immunotolerant allogenic cell transplants revealed
Researchers for the first time have found a way to prevent immune rejection of allogenic iPSC-derived cell and tissue transplants.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
Entries by Thomas Gabrielczyk
Digital solutions to serialisation
Its only been nine years since the first blockchain technology applications in finance were introduced. Big players are now working to use distributed computing to protect pharma logistics from counterfeit drugs. Unlike current Internet-based solutions, the decentralised blockchain network is immune to manipulation or hacks, as transactions can be verified, recorded, and coordinated autonomously without third-party involvement.
Arvelle Therapeutics raises $180m in Series A financing
Swiss newco Arvelle Therapeutics has baged a $180m (€159.1m) series A financing led by LSP. The company licenced the anti-epileptic candidate cenobamate (YKP3089) for $100m (€88.4m) upfront from SK Biopharmaceuticals.
Bio-plastics production grows to 7.5 million tonnes
The market for bio-based building blocks and polymers showed moderate growth to 7.5 million tonnes in 2018 and will grow with a CGAR of 4% by 2023 reports German nova-Institute.
Reprogrammed pancreatic cells cure type I diabetes
Swiss researchers have demonstrated a way to cure type I diabetes without cell transplantation. In model mice the reprogrammed non-islet cells from human pancreas
Afyren raises €21m to launch production plant
French industrial biotech company Afyren announced a capital increase of €21m in a financing round led by Sofinnova Partners and Valquest Partners to scale up its biobased organic acid production to industrial scale.
Race against time
After a quick start out the gates in 2012, the European Commission proceeded to carry out a lengthy review of its bioeconomy strategy – slamming the brakes on investor interest in EU biotechs developing solutions for the move to a low-carbon, zero-waste economy. Following several reports that suggested the bloc will miss internationally agreed sustainability targets, the EC now wants to speed up the switch to biobased production. Industry stakeholders presented a huge range of promising technologies at the EFIB, but are still awaiting the go-ahead.
Industrial biotech hub validates start-up ideas
Biotech Campus Delft, Royal DSM and YES!Delft partner up have launched a Biotech Validation Lab to validate the business concepts of European biotech startups.
uniqure delivers POC for hemophilia B gene therapy
Gene therapy uniQure NV (Amsterdam) reported that factor IX levels of patients with severe hemophilia B raised to a mean of 38% of normal 12 weeks after a single injection of AMT-061.
Ose Pharma gets clinical milestone for IL7R antagonist
Ose Immunotherapeutics has got the first milestone payment within its €272m deal with Servier inked in 2016.